Genmab to Showcase 23 Oncology Abstracts at ASCO and EHA 2026
Event summary
- Genmab will present 23 abstracts at ASCO (May 29-June 2) and EHA (June 11-14) 2026, including 20 on epcoritamab.
- Key data includes Phase 3 EPCORE® DLBCL-1 trial results comparing epcoritamab to chemotherapy in relapsed/refractory large B-cell lymphoma.
- Three abstracts will showcase ongoing trials for rinatabart sesutecan and petosemtamab.
- Epcoritamab data will cover monotherapy, combination regimens, fixed-duration use, and earlier lines of treatment.
The big picture
Genmab's extensive data presentation at ASCO and EHA 2026 underscores its leadership in antibody-based oncology therapies. The focus on epcoritamab's versatility across multiple treatment settings highlights its potential as a core therapy for B-cell malignancies. The collaboration with AbbVie for global commercialization positions Genmab to capitalize on the growing demand for targeted cancer treatments.
What we're watching
- Clinical Efficacy
- How the full Phase 3 EPCORE® DLBCL-1 trial results will impact epcoritamab's regulatory approval prospects.
- Commercial Strategy
- Whether Genmab and AbbVie can sustain the global expansion of epcoritamab across multiple hematologic malignancies.
- Pipeline Progress
- The pace at which rinatabart sesutecan and petosemtamab advance through late-stage trials.
Related topics